miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer
© Augoff et al; licensee BioMed Central Ltd. 2012
Received: 25 August 2011
Accepted: 30 January 2012
Published: 30 January 2012
microRNAs have been established as powerful regulators of gene expression in normal physiological as well as in pathological conditions, including cancer progression and metastasis. Recent studies have demonstrated a key role of miR-31 in the progression and metastasis of breast cancer. Downregulation of miR-31 enhances several steps of the invasion-metastasis cascade in breast cancer, i.e., local invasion, extravasation and survival in the circulation system, and metastatic colonization of distant sites. miR-31 exerts its metastasis-suppressor activity by targeting a cohort of pro-metastatic genes, including RhoA and WAVE3. The molecular mechanisms that lead to the loss of miR-31 and the activation of its pro-metastatic target genes during these specific steps of the invasion-metastasis cascade are however unknown.
In the present report, we identify promoter hypermethylation as one of the major mechanisms for silencing miR-31 in breast cancer, and in the triple-negative breast cancer (TNBC) cell lines of basal subtype, in particular. miR-31 maps to the intronic sequence of a novel long non-coding (lnc)RNA, LOC554202 and the regulation of its transcriptional activity is under control of LOC554202. Both miR-31 and the host gene LOC554202 are down-regulated in the TNBC cell lines of basal subtype and over-expressed in the luminal counterparts. Treatment of the TNBC cell lines with either a de-methylating agent alone or in combination with a de-acetylating agent resulted in a significant increase of both miR-31 and its host gene, suggesting an epigenetic mechanism for the silencing of these two genes by promoter hypermethylation. Finally, both methylation-specific PCR and sequencing of bisulfite-converted DNA demonstrated that the LOC554202 promoter-associated CpG island is heavily methylated in the TNBC cell lines and hypomethylated in the luminal subtypes.
Loss of miR-31 expression in TNBC cell lines is attributed to hypermethylation of its promoter-associated CpG island. Together, our results provide the initial evidence for a mechanism by which miR-31, an important determinant of the invasion metastasis cascade, is regulated in breast cancer.
KeywordsmiR-31 LOC554202 Triple-negative breast cancer lncRNA CpG hypermethylation Invasion-metastasis cascade
Metastasis is responsible for ~90% of deaths in patients with solid tumors [1–4], including those originating in the breast [5–7]. Metastasis has always been portrayed as the ultimate step of the progressing breast cancers. Recent evidence, however, indicates that about a third of women diagnosed with small asymptomatic breast tumors (~4 mm) already harbor disseminated BC cells in their bone marrow . Moreover, these micrometastases can remain dormant for years before reemerging as incurable secondary tumors and surprisingly insensitive to adjuvant chemotherapies that were originally effective against the primary tumor [9, 10]. Adding to this problem is the fact that BC is a heterogeneous disease comprised of at least 5 genetically distinct subtypes, which together are the second leading cause of cancer deaths in women in the United States [11–13]. Within BC subtypes, those classified as Triple-Negative BCs (TNBCs) exhibit dismal survival rates due to their highly aggressive and metastatic behavior, and to their propensity to rapidly recur [14–20]. The TNBC subtype is characterized by lack of expression of hormone receptors (ER-α and PR) and HER2, harbor BRCA1-defects and/or deficiencies, and remain p53-positive [14, 16–20]. Moreover, the absence of novel therapies capable of specifically targeting this very aggressive TNBC subtype reflects in part a lack of sufficient knowledge about TNBC development and progression [2, 4, 9, 21].
microRNAs (miRs) are small noncoding RNAs, usually 20- to 22-nucleotides long, which regulate gene expression at the post-transcriptional level. To date, close to 1000 human miRs have been identified, which are thought to regulate more than 50% of human genes. miRs are now widely regarded as the most powerful regulators of gene expression in complex cellular processes including cancer cell invasion and metastasis [1, 22–25]. In fact, several miRs, miR-15a, miR-16-1, and let-7 [23, 26–30] function as tumor suppressors, and others, miR-155, miR-17-5p, and miR-21 [23, 31, 32], possess oncogenic properties
Several recent reports have identified a major role of miR31 in cancer metastasis [33–36] With regard to BC, we reported that miR-31 expression is lost in aggressive basal-type breast cancer cell lines compared to the non-invasive luminal counterparts. This observation was extended to human breast cancer tumors where we found an inverse correlation between miR-31 expression levels and advanced stages of BC . Also, in our previously published work, we reported a highly significant correlation between the expression levels of WAVE3 and advanced stages of BC , supporting the function of WAVE3 as a metastasis promoter protein [38–40]. Linking these observations, we found that miR-31 regulated WAVE3 expression and activity during the invasion-metastasis cascade [24, 25]. However, the upstream mechanisms of transcriptional regulation of miR-31 are not well understood and are the focus of the present study.
A recent study has predicted miR-31 to be transcribed from within the first intron of a host gene, LOC554202, on human chromosome 9 . Our in silico analyses have confirmed these findings and suggest that LOC554202 is transcribed into a long non-coding RNA, (Lnc)RNA. We also identified a major CpG island upstream of the miR-31 locus, which also spans the first exon of LOC554202, suggesting an epigenetic regulation by methylation of both miR31 and its host gene. Here, we report that the expression pattern of miR-31 follows that of LOC554202 in the TNBC basal versus the luminal BC cell lines, supporting the hypothesis that miR-31 is under the transcriptional regulation as LOC554202. Next we show that loss of miR-31 expression in the aggressive TNBC cell lines is a direct consequence of hypermethylation of its associated promoter which also regulates LOC554202, the host gene for miR-31. Using both methylation-specific PCR (MSP) and bisulfite-modified DNA sequencing, we directly demonstrate that the miR-31 promoter is heavily methylated in basal TNBC compared to luminal BC cell lines. Our results not only identify a novel mechanism for miR-31 regulation but also clearly support the important role of promoter methylation in the suppression of miR-31 during tumor progression.
miR-31 is transcribed from within the intronic sequence of a long non-coding (lnc)RNA, LOC554202
We also used genomic PCR analysis to show that all 4 exons of LOC554202 and miR-31 can be amplified from the genomic DNA of each of breast cancer cell lines we used in this study (Figure 2B). We, therefore, confirmed the integrity of the LOC554202 gene in these cell lines, and ruled out gross genomic alterations as a possible mechanism for the regulation of expression of both LOC554202 and miR-31.
miR-31 and its host gene LOC554202 are down-regulated in TNBCs
miR-31 and its host gene LOC554202 are epigenetically regulated in the TNBCs
CpG island methylation plays an important role in silencing of both the LOC554202 and miR-31 genes
Altered expression of microRNAs is frequently observed in human cancer, including ones originating in the breast [44–46], but the mechanisms underlying their regulation are poorly understood. We and others have previously shown that miR-31, a BC metastasis suppressor gene, is a major contributor to BC progression and metastasis by regulating a cohort of a pro-metastatic target genes, including WAVE3 , RhoA, Radexin  and several integrin subunits  that regulate key steps in the invasion-metastasis cascade. miR-31 expression levels are high in early stage BC tumors, allowing for its pro-invasive, pro-metastatic target genes to remain under tight control [24, 36]. Expression levels of miR-31diminish as the tumors progress to more invasive stages  and become undetectable in metastatic BC tumors . Loss of miR-31 expression is accompanied by concomitant increase in expression of its pro-invasive and pro-metastatic target genes, therefore, allowing for the tumor to become more invasive and ultimately metastasizes [24, 36]. In BC mouse models, re-expression of miR-31 in the triple-negative MDA-MB-231 BC cells, which do not express endogenous miR-31, almost completely inhibits the metastatic potential of these cells without affecting the growth of the primary tumors while specifically inhibiting its pro-metastatic target genes ( and Sossey-Alaoui, unpublished data). On the other hand, knockdown of miR-31 in the non invasive luminal MCF7 BC cells results in lifting the inhibitory effect imposed by miR-31 on its target genes and imparts aggressive and metastatic phenotype to these cells comparable to observed in MDA-MB-231 cells [24, 36]. Together, these published studies clearly demonstrate the important role that miR-31 plays during the invasion-metastasis cascade of BC tumors.
The mechanisms for upstream regulation of miR-31 leading to its loss during the invasion-metastasis cascade has been heretofore unknown. In this study, we report the contribution of epigenetic modifications as a novel mechanism by which miR-31 is regulated in breast cancer. First we showed that miR-31 is transcribed from the intronic sequence of LOC554202, a newly identified lncRNA. While both miR-31 and its host gene LOC554202 are expressed abundantly in the non-invasive BC cell lines of luminal subtype, their expression is lost in more aggressive TNBC cell lines of basal subtype, clearly suggesting that the transcription regulation of miR-31 might be under the control of its host gene LOC554202. Second, we identified a strong CpG island in the LOC554202-associated promoter, prompting us to hypothesize that both miR-31 in its host gene might be regulated by promoter methylation. Indeed, we were able to enhance expression of both miR-31 and LOC554202 in the TNBC cell lines after treatment with either the methylase inhibitor 5Aza2Cd alone or in combination with the acetylase inhibitor TSA. To further confirm the contribution of promoter hypermethylation to the loss of miR-31 in the TNBC cell lines we performed both methylation specific PCR and sequencing of bisulfite-modified DNA from both luminal (MCF7) and basal TNBC (MDA-MB-231 and BT549) cell lines. The combined number of CpG dinucleotides surveyed by these two assays allowed coverage of at least one third of total length of the CpG island. We found that while the LOC554201-associated promoter was significantly hypermethylated the in basal TNBCs, it was significantly hypomethylated in the luminal counterpart, further confirming that miR-31 expression is regulated in the TNBCs at least in part by promoter methylation. It is well established that hypermethylation of CpG islands associated with specific genes increases during the growth and progression of the primary tumor, providing a mechanism to inactivate tumor suppressor genes, DNA repair genes, cell cycle regulators and transcription factors. Based on our RT-PCR results, treatment of the TNBC cells with 5Aza2Cd or in combination with TSA enhanced expression of both miR-31 and its host gene LOC554202 to levels similar to those found in luminal BC subtypes. The restoration of miR-31 expression by these maneuvers was also very significant but did not reach the levels observed in luminal BC (Figure 3). One possible explanation for this difference is that, in addition to promoter methylation that regulates both miR-31 and LOC554202, other mechanisms may selectively regulate miR-31.
It is worth noting that our study appears to be the first to report that LOC554202 might belong to the lncRNA family. Our preliminary in silico analyses show that the LOC554202 locus spans more that 100 kilobases (kb) of genomic sequence and that its RNA is transcribed from 4 exons resulting in a spliced transcript of ~2.2 kb (Figure 1), which does not contain an open-reading frame that could be translated into a functional protein, and therefore can be classified a lncRNA. It is possible that this new lncRNA may have a function in chromatin remodeling and epigenetic regulation of gene expression similar to that of the well known XIST and HOTAIR lncRNAs [48, 49]. More experimental analyses are however required to investigate the exact function of LOC554202 in breast cancer invasion and metastasis.
The present study, although conducted in established cell lines, clearly identifies promoter hypermethylation as a novel mechanism by which miR-31 is silenced during the invasion-metastasis cascade of BC. Future studies using biological specimens with associated clinico-pathological parameters and disease outcome, are required to further confirm these findings and to assess whether miR-31 promoter methylation can be used a prognostic marker for BC progression and survival outcome.
Cell lines and their treatment
Human non-malignant breast epithelial cell line MCF10A and the human breast cancer cell lines were obtained from American Type Culture Collection (Rockville, MD). Cells were cultured at 37°C with 5% CO2 in their specified basic culture medium supplemented with 4.5 g/L glucose, 10% fetal bovine serum (Invitrogen), 2 mmol/L glutamine and antibiotics. The demethylating agent 5Aza2dC (Sigma, MO, USA) was freshly prepared in double-distilled H2O and filter sterilized. Cells (5-10 × 105) were seeded in a 100 mm tissue culture dish in culture medium at 37°C, 10% CO2. The next day, cells were treated with 0.5 μM of 5aza2dC. The culture medium containing the demethylating agent was replaced every day for 7 days. For the 5Aza2dC-Trichostatin A (TSA, Sigma, MO, USA) dual treatment, TSA (0.3 μM final concentration) was added to the culture at day 5 for a 48-h treatment period. At the end of the treatment period, total RNA was prepared using TRIzol (Invitrogen, CA, USA), according to the manufacturer's instructions. The BAC clones were obtained from the Rowell Park Cancer Institute BAC Library and BAC DNA was isolated using the the QIAprep Spin Miniprep kit (Qiagen Sciences, MD, USA). The total genomic DNA was prepared using proteinase K digestion as previously described .
Semi-quantitative and Real-time quantitative-PCR
Total RNA was extracted from cancer cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA), following to the manufacturer's instructions. cDNA was generated and used as a template for semi-quantitative RT-PCR performed as previously described [25, 37, 51, 52]. Expression levels of the precursor (pri-miR) and the mature forms of microRNA miR-31 were quantified by real-time quantitative RT-PCR using human TaqMan MicroRNA Assays Kits (Applied Biosystems, Carlsbad, CA). We used GAPDH to normalize the expression levels of LOC554202 transcripts. In addition, we found that both miR-16 and RNU6B were expressed at similar levels in all cell lines analyzed, when normalized to GAPDH (Additional File 1). Furthermore, treatment of BC cells with either 5Aza2dC, Trichostatin A or both, did not affect their expression levels when compared to the untreated cells (Additional File 1), and therefore, were used for normalization of miR-31 expression levels across the breast cancer cell lines and between treatments. The reverse transcription reaction was carried out with TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) following the manufacturer's instructions. Quantitative PCR was performed on the BioRad (Hercules, CA) MyiQ2 iCycler PCR system where the reaction mixtures were incubated at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The cycle threshold (Ct) values were calculated with SDS 1.4 software (Bio-Rad). The expression levels of miR-31 were normalized using the 2-ΔΔCt method  relative to miR-16 or RNU6B. The ΔCt was calculated by subtracting the Ct values of miR-16 from the Ct values of miR-31. The ΔΔCt was then calculated by subtracting ΔCt of each breast cancer cell line from MCF10 cells. Fold change in the gene expression was calculated according to the equation 2-ΔΔCt.
Preparation of bisulfite-modified DNA for methylation analysis
Genomic DNA (1-2 μg) was denatured in 0.3 M NaOH for 30 min at 42°C, and then the unmethylated cytosine residues were sulphonated by incubation in 3.12 M sodium bisulfite (pH 5.0; Sigma)/5 mM hydroquinone (Sigma, MO, USA) at 55°C for 16 h. The sulphonated DNA was recovered using the QIAquick Gel Extraction system (Qiagen, MA, USA), according to the manufacturer's recommendations. The conversion reaction was completed by desulphonating in 0.3 M NaOH for 5 min at room temperature. The DNA was ethanol precipitated and resuspended in double-distilled water.
CpG island prediction and primer design for methylation analysis
The LOC554202 putative promoter region was predicted from the genomic sequence of BAC clone RP11-344A7, accession number AL137022, for the sequence around its first exon using the PromoterInspector prediction software (http://www.genomatix.ed). The promoter-associated CpG island was predicted using the CpG prediction algorithm (http://www.urogene.org/methprimer/help.html#cpg_prediction), and primers for sequencing of bisulfite-modified DNA and for methylation specific PCR (Additional File 2) were designed using the Methprimer algorithm (http://www.urogene.org/methprimer/index.html).
Sequencing of bisulfite-modified DNA
In total, 20-50 ng of bisulfite-treated DNA was used as template in each PCR reaction under the following conditions: 95°C for 5 min, followed by 40 cycles of 15 s of denaturation at 95°C, 20 sec at 55°C and 25 sec of extension at 72°C. The PCR reaction was terminated with an additional 7 min of extension and cooled to 4°C. The PCR products were resolved on a 2% agarose gel, stained with ethidium bromide, and the 250-bp bands were excised and gel-purified using the QIAquick Gel Extraction system (Qiagen, MA, USA). The purified PCR products were cloned into the pCR2·1-TOPO vector (Invitrogen, CA, USA), and at least 15 clones were sequenced from each cell line. The methylation status at each CpG site was analyzed using the MethTools software (http://genome.imb-jena.de/methtools/). The overall methylation status in each cell line was calculated as a ratio of the number of unmethylated to methylated CpGs and plotted as a percentage of total number of CpGs analyzed.
Methylation specific PCR
Methylation specific PCR (MSP) was performed on bisufite-converted DNA using the MSP primer pairs described in Additional file 2. Each DNA sample was PCR-amplified using either the methylated or the unmethylated primer pairs. The PCR products were next resolved by agarose electrophoresis, stained with ethidium bromide and a picture recorded. The intensities of the PCR products between the methylated and unmethylated primer-pairs were compared by densitometry.
Oligonucleotide primer sequences
Sequences of the oligonucleotide primers used for genomic PCR, RT-PCR from IDT (San Diego, CA) and are listed Additional file 2.
The data are presented as the means ± standard errors of at least three independent experiments. The results were tested for significance using an unpaired Student's t test and p values of < 0.05 were considered statistically significant.
Wisckott aldrich verprolin family member 3
Triple-negative breast cancer
Epithelial to mesenchymal transition
Bacterial artificial chromosome
Polymerase chain reaction
Reverse transcriptase PCR
Quantitative real-time RT-PCR
Methylation specific PCR
- Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP: Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 2007, 24: 587-597. 10.1007/s10585-007-9114-6View ArticlePubMedGoogle Scholar
- Chiang AC, Massague J: Molecular basis of metastasis. N Engl J Med. 2008, 359: 2814-2823. 10.1056/NEJMra0805239PubMed CentralView ArticlePubMedGoogle Scholar
- Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T, Brabletz T: Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol. 2007, 91: 21-28.PubMedGoogle Scholar
- Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009, 9: 274-284. 10.1038/nrc2622View ArticlePubMedGoogle Scholar
- May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA: Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011, 13: 202-PubMed CentralView ArticlePubMedGoogle Scholar
- Taylor MA, Parvani JG, Schiemann WP: The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia. 2010, 15: 169-190. 10.1007/s10911-010-9181-1PubMed CentralView ArticlePubMedGoogle Scholar
- Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008, 14: 818-829. 10.1016/j.devcel.2008.05.009View ArticlePubMedGoogle Scholar
- Talmadge JE, Fidler IJ: AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010, 70: 5649-5669. 10.1158/0008-5472.CAN-10-1040PubMed CentralView ArticlePubMedGoogle Scholar
- Gupta GP, Massague J: Cancer metastasis: building a framework. Cell. 2006, 127: 679-695. 10.1016/j.cell.2006.11.001View ArticlePubMedGoogle Scholar
- Li F, Tiede B, Massague J, Kang Y: Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007, 17: 3-14. 10.1038/sj.cr.7310118View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073View ArticlePubMedGoogle Scholar
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093View ArticlePubMedGoogle Scholar
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098PubMed CentralView ArticlePubMedGoogle Scholar
- Anders C, Carey LA: Understanding and treating triple-negative breast cancer. Oncology (Williston Park). 2008, 22: 1233-1239.Google Scholar
- Anders CK, Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009, 9 (Suppl 2): S73-S81.PubMed CentralView ArticlePubMedGoogle Scholar
- Carey L, Winer E, Viale G, Cameron D, Gianni L: Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol. 2010, 7: 683-692. 10.1038/nrclinonc.2010.154View ArticlePubMedGoogle Scholar
- Finnegan TJ, Carey LA: Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol. 2007, 3: 55-63. 10.2217/147966220.127.116.11View ArticlePubMedGoogle Scholar
- Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 2010, 363: 1938-1948. 10.1056/NEJMra1001389View ArticlePubMedGoogle Scholar
- Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE: RB1 and p53 at the crossroad of EMT and triple negative breast cancer. Cell Cycle. 2011, 10: 1563-1570. 10.4161/cc.10.10.15703View ArticlePubMedGoogle Scholar
- Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14: 8010-8018. 10.1158/1078-0432.CCR-08-1208View ArticlePubMedGoogle Scholar
- Padua D, Massague J: Roles of TGFbeta in metastasis. Cell Res. 2009, 19: 89-102. 10.1038/cr.2008.316View ArticlePubMedGoogle Scholar
- Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9: 582-589. 10.1038/embor.2008.74PubMed CentralView ArticlePubMedGoogle Scholar
- Esquela-Kerscher A, Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840View ArticlePubMedGoogle Scholar
- Sossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R, Plow EF: WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int J Cancer. 2011, 129 (6): 1331-1343. 10.1002/ijc.25793PubMed CentralView ArticlePubMedGoogle Scholar
- Sossey-Alaoui K, Bialkowska K, Plow EF: The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem. 2009, 284: 33019-33029. 10.1074/jbc.M109.034553PubMed CentralView ArticlePubMedGoogle Scholar
- Akao Y, Nakagawa Y, Naoe T: let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006, 29: 903-906. 10.1248/bpb.29.903View ArticlePubMedGoogle Scholar
- Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002, 99: 15524-15529. 10.1073/pnas.242606799PubMed CentralView ArticlePubMedGoogle Scholar
- Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007, 67: 7713-7722. 10.1158/0008-5472.CAN-07-1083View ArticlePubMedGoogle Scholar
- Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64: 3753-3756. 10.1158/0008-5472.CAN-04-0637View ArticlePubMedGoogle Scholar
- Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006, 9: 189-198. 10.1016/j.ccr.2006.01.025View ArticlePubMedGoogle Scholar
- He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S: A microRNA polycistron as a potential human oncogene. Nature. 2005, 435: 828-833. 10.1038/nature03552View ArticlePubMedGoogle Scholar
- Voorhoeve PM, le SC, Schrier M, Gillis AJ, Stoop H, Nagel R: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006, 124: 1169-1181. 10.1016/j.cell.2006.02.037View ArticlePubMedGoogle Scholar
- Valastyan S, Weinberg RA: miR-31: A crucial overseer of tumor metastasis and other emerging roles. Cell Cycle. 2010, 9: 2124-2129. 10.4161/cc.9.11.11843View ArticlePubMedGoogle Scholar
- Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA: Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev. 2011, 25: 646-659. 10.1101/gad.2004211PubMed CentralView ArticlePubMedGoogle Scholar
- Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA: Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev. 2009, 23: 2592-2597. 10.1101/gad.1832709PubMed CentralView ArticlePubMedGoogle Scholar
- Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009, 137: 1032-1046. 10.1016/j.cell.2009.03.047PubMed CentralView ArticlePubMedGoogle Scholar
- Sossey-Alaoui K, Safina A, Li X, Vaughan MM, Hicks DG, Bakin AV: Down-Regulation of WAVE3, a Metastasis Promoter Gene, Inhibits Invasion and Metastasis of Breast Cancer Cells. Am J Pathol. 2007, 170 (6): 2112-2121. 10.2353/ajpath.2007.060975PubMed CentralView ArticlePubMedGoogle Scholar
- Fernando HS, Davies SR, Chhabra A, Watkins G, Douglas-Jones A, Kynaston H: Expression of the WASP verprolin-homologues (WAVE members) in human breast cancer. Oncology. 2007, 73: 376-383. 10.1159/000136157View ArticlePubMedGoogle Scholar
- Fernando HS, Sanders AJ, Kynaston HG, Jiang WG: WAVE3 is associated with invasiveness in prostate cancer cells. Urol Oncol. 2009, 28 (3): 320-327.View ArticlePubMedGoogle Scholar
- Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E: Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res. 2004, 64: 8585-8594. 10.1158/0008-5472.CAN-04-1136View ArticlePubMedGoogle Scholar
- Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV: Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One. 2009, 4: e5279- 10.1371/journal.pone.0005279PubMed CentralView ArticlePubMedGoogle Scholar
- Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R: Complete sequencing and characterization of 21, 243 full-length human cDNAs. Nat Genet. 2004, 36: 40-45. 10.1038/ng1285View ArticlePubMedGoogle Scholar
- Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS: Generation and initial analysis of more than 15, 000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA. 2002, 99: 16899-16903. 10.1073/pnas.242603899View ArticlePubMedGoogle Scholar
- Bachour T, Bennett K: The Role of MicroRNAs in Breast Cancer. J Assoc Genet Technol. 2011, 37: 21-28.PubMedGoogle Scholar
- Andorfer CA, Necela BM, Thompson EA, Perez EA: MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 2011, 17: 313-319. 10.1016/j.molmed.2011.01.006View ArticlePubMedGoogle Scholar
- Weigel MT, Dowsett M: Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010, 17: R245-R262. 10.1677/ERC-10-0136View ArticlePubMedGoogle Scholar
- Augoff K, Das M, Bialkowska K, McCue B, Plow EF, Sossey-Alaoui K: miR-31 is a broad regulator of β1-integrin expression and function in cancer cells. Mol Cancer Res. 2011, 9 (11): 1500-1508. 10.1158/1541-7786.MCR-11-0311PubMed CentralView ArticlePubMedGoogle Scholar
- Wapinski O, Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol. 2011, 21: 354-361. 10.1016/j.tcb.2011.04.001View ArticlePubMedGoogle Scholar
- Nagano T, Fraser P: Emerging similarities in epigenetic gene silencing by long noncoding RNAs. Mamm Genome. 2009, 20: 557-562. 10.1007/s00335-009-9218-1View ArticlePubMedGoogle Scholar
- Sossey-Alaoui K, Kitamura E, Head K, Cowell JK: Characterization of FAM10A4, a member of the ST13 tumor suppressor gene family that maps to the 13q14.3 region associated with B-Cell leukemia, multiple myeloma, and prostate cancer. Genomics. 2002, 80: 5-7. 10.1006/geno.2002.6792View ArticlePubMedGoogle Scholar
- Sossey-Alaoui K, Ranalli TA, Li X, Bakin AV, Cowell JK: WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Exp Cell Res. 2005, 308: 135-145. 10.1016/j.yexcr.2005.04.011View ArticlePubMedGoogle Scholar
- Sossey-Alaoui K, Li X, Cowell JK: c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration. J Biol Chem. 2007, 282: 26257-26265. 10.1074/jbc.M701484200View ArticlePubMedGoogle Scholar
- Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited